Search Result

Results for "

Cannabinoid Receptor

" in MCE Product Catalog:

By Targets:	Cannabinoid Receptor (88) 5-HT Receptor (1) Androgen Receptor (1) Autophagy (9) Bacterial (4) Biochemical Assay Reagents (1) Cytochrome P450 (1) Endogenous Metabolite (15) FAAH (1) Fatty Acid Synthase (FASN) (1) GPR55 (2) Isotope-Labeled Compounds (1) NF-κB (1) NO Synthase (2) P-glycoprotein (1) PDHK (1) TRP Channel (11)
By Research Areas:	Cancer (11) Cardiovascular Disease (1) Endocrinology (1) Infection (4) Inflammation/Immunology (13) Metabolic Disease (18) Neurological Disease (56)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: Cannabinoid Receptor

Cat. No.	Product Name	Target	Research Areas

HY-117139

NESS 0327	Cannabinoid Receptor	Neurological Disease
NESS 0327 is a *cannabinoid* antagonist with high selectivity for the cannabinoid CB1 receptor. NESS 0327 is more than 60,000-fold selective for the CB1 receptor.

HY-152270

Pirnabine
Cannabinoid Receptor Neurological Disease

Pirnabine is a cannabinoid receptor ligand. Pirnabine can be used for the research of glaucoma.

Pirnabine	Cannabinoid Receptor	Neurological Disease
Pirnabine is a **cannabinoid receptor** ligand. Pirnabine can be used for the research of glaucoma.

HY-103336

Tocrifluor 1117 T1117	GPR55 Cannabinoid Receptor	Cardiovascular Disease
Tocrifluor 1117 (T1117), a fluorescent form of the cannabinoid CB1 receptor antagonist AM251 (HY-15443), is a selective fluorescent GPR55 ligand. Tocrifluor 1117 is a potent tool for identifying the cellular location of cannabinoid receptors (including GPR55 in living tissues) (Ex/Em=543/590 nm).

HY-133533

O-2050	Cannabinoid Receptor	Neurological Disease
O-2050 is a high affinity **cannabinoid CB₁ receptor antagonist with a K_i** of 2.5 nM. O-2050 inhibits cannabinoid CB₂ receptor (K_i=0.2 nM). O-2050 can cause locomotor stimulation in mice.

HY-N2911

Auriculasin	Cannabinoid Receptor	Neurological Disease
Auriculasin is a nature product isolated from *Limonium leptophyllum. Auriculasin has activity toward cannabinoid* receptor type 1 (CB1) with an IC₅₀ value of 8.92 µM.

HY-151105

CBR Agonist-1	Cannabinoid Receptor	Neurological Disease
CBR Agonist-1 (27a-cis) is a cannabinoid receptor (CBR) agonist with the K_i values of 0.18 μM for CB₁R and 1.22 μM for CB₂R. CBR Agonist-1 (27a-cis) can be used in the study of endogenous cannabinoid system-related diseases.

HY-113689

GAT211	Cannabinoid Receptor	Neurological Disease
GAT211 is a cannabinoid 1 receptor (CB1R) positive allosteric modulator (PAM). GAT211 activates cAMP and β-arrestin2 with EC₅₀ values of 260 nM and 650 nM, respectively. GAT211 inhibits GAT211 can be used for neuropathic and/or inflammatory pain research.

HY-110050

GP1a	Cannabinoid Receptor	Inflammation/Immunology Neurological Disease
GP1a is a potent agonist of cannabinoid receptor 2 (CB2). Gp1a is beneficial to skin wound healing. GP1a inhibits inflammation and fibrogenesis while promoting re-epithelialization.

HY-N6932

Voacamine	Cannabinoid Receptor P-glycoprotein	Cancer Metabolic Disease
Voacamine, an indole alkaloid, exhibits potent **cannabinoid CB1 receptor antagonistic activity. Voacamine also inhibits P-glycoprotein (P-gp**) action in multidrug-resistant tumor cells.

HY-145604

Vicasinabin RG7774	Cannabinoid Receptor	Neurological Disease
Vicasinabin (RG7774) is the potent agonist of cannabinoid receptor 2 (CB2). Vicasinabin has the potential for the research of human diseases including chronic pain, atherosclerosis, regulation of bone mass, neuroinflammation, and other related diseases (extracted from patent US20130116236A1).

HY-110206

AM6545	Cannabinoid Receptor	Metabolic Disease
AM6545 is a peripherally active, **cannabinoid receptor antagonist with limited brain penetration. AM6545 binds to CB1 and CB2** receptors with K_is of 1.7 nM and 523 nM, respectively. AM6545 is a neutral antagonist. AM6545 can be used for the research of obesity and its complications.

HY-144827

AM8936	Cannabinoid Receptor	Neurological Disease Metabolic Disease
AM8936 acts as a balanced and potent cannabinoid receptor type-1 (CB1) agonist in functional assays (EC₅₀s of 8.6 and 1.4 nM for rCB1 and hCB1, respectively). AM8936 exhibits high affinity for rat CB1 (rCB1) with K_i of 0.55 nM. AM8936 is a potent and efficacious CB1 agonist in vivo. AM8936 can be used for the research of CNS and metabolic disorders, pain, glaucoma, etc.

HY-135882

OMDM-6	TRP Channel Cannabinoid Receptor Endogenous Metabolite	Neurological Disease
OMDM-6 is a hybrid agonist of *vanilloid receptor* type 1 (VR1, TRPV1) (EC₅₀*=75 nM) and cannabinoid* receptor type 1 (CB1) (K_i=3.2 μM). OMDM-6 inhibits anandamide cellular uptake (ACU) with a K_i of 7.0 μM.

HY-135881

OMDM-5	TRP Channel Endogenous Metabolite	Neurological Disease
OMDM-5 is a selective inhibitor of anandamide cellular uptake (ACU), with a K_i of 4.8 μM. OMDM-5 is also a potent *vanilloid receptor* type 1 (VR1, TRPV1) agonist, with an EC₅₀** of 75 nM, and shows weakly active as cannabinoid receptor type 1 (CB1) ligand (K_i=4.9 μM).

HY-152251

CB2R/FAAH modulator-1	Cannabinoid Receptor FAAH	Inflammation/Immunology
CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with K_is of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production.

HY-14791A

(±)-Ibipinabant (±)-SLV319; (±)-BMS-646256	Cannabinoid Receptor	Metabolic Disease
(±)-Ibipinabant ((±)-SLV319) is the racemate of SLV319. (±)-Ibipinabant ((±)-SLV319) is a potent and selective cannabinoid-1 (CB-1) receptor antagonist with an IC₅₀ of 22 nM.

HY-P1397

RVD-Hpα	Cannabinoid Receptor	Neurological Disease
RVD-Hpα, an α-hemoglobin-derived peptide containing three additional amino acids, is a CB1 cannabinoid receptor agonist. RVD-Hpα is a positive allosteric modulator of cannabinoid receptor 2.

HY-10013A

Taranabant racemate MK-0364 racemate	Cannabinoid Receptor	Neurological Disease
Taranabant racemate (MK-0364 racemate) is an antagonist and/or inverse agonist of the *Cannabinoid-1* (CB1) *receptor* extracted from patent WO 2004048317 A1.

HY-120423

AM-6538	Cannabinoid Receptor	Neurological Disease
AM6538 is a long-acting, high affinity and pseudo-irreversible cannabinoid (CB) antagonist. AM6538 is a structural analog of rimonabant. AM6538 can be effectively used to evaluate the apparent efficacy of cannabinoid full and partial agonists. AM6538 may be useful in future studies that require temporary reductions in cannabinoid receptor availability.

HY-120953

GAT228
Cannabinoid Receptor Inflammation/Immunology

GAT228, the enantiomer of GAT211, is an allosteric cannabinoid receptor 1 (CB1) ligand.
HY-12761

A-836339
Cannabinoid Receptor Neurological Disease

A-836339 is a cannabinoid CB2 receptor-selective agonist; exhibits high potencies at CB(2) and selectivity over CB(1) receptors.
HY-100328

CB2R-IN-1
Cannabinoid Receptor Neurological Disease

CB2R-IN-1 is a potent cannabinoid CB₂ receptor inverse agonist with a K_i of 0.9 nM.

GAT228	Cannabinoid Receptor	Inflammation/Immunology
GAT228, the enantiomer of GAT211, is an allosteric cannabinoid receptor 1 (CB1) ligand.

A-836339	Cannabinoid Receptor	Neurological Disease
A-836339 is a cannabinoid CB2 receptor-selective agonist; exhibits high potencies at CB(2) and selectivity over CB(1) receptors.

CB2R-IN-1	Cannabinoid Receptor	Neurological Disease
CB2R-IN-1 is a potent cannabinoid CB₂ receptor inverse agonist with a K_i of 0.9 nM.

HY-10871A

Otenabant Hydrochloride CP 945598 Hydrochloride	Cannabinoid Receptor	Metabolic Disease
Otenabant Hydrochloride is a potent and selective cannabinoid receptor CB1 antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

HY-10871

Otenabant CP-945598	Cannabinoid Receptor	Metabolic Disease
Otenabant is a potent and selective cannabinoid receptor CB1 antagonist with K_i of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.

HY-N0919

Yangonin	Cannabinoid Receptor NF-κB Autophagy	Inflammation/Immunology
Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC₅₀ and a K_i of 1.79 μM and 0.72 μM, respectively.

HY-150067

CB1R antagonist 1	Cannabinoid Receptor	Metabolic Disease
CB1R Allosteric modulator 5, a selective cannabinoid-1 receptor (CB1R) inverse agonist with an IC₅₀ value of 4.2 μM and EC₅₀ value of ＞10 μM. CB1R Allosteric modulator 5 can be used for the research of metabolic and obesity.

HY-146134

PGN36
Cannabinoid Receptor Inflammation/Immunology

PGN36 (Compound 18) is a selective cannabinoid CB₂ receptor (CB₂R) antagonist with a K_i of 0.09 µM.

PGN36	Cannabinoid Receptor	Inflammation/Immunology
PGN36 (Compound 18) is a selective cannabinoid CB₂ receptor (CB₂R) antagonist with a K_i of 0.09 µM.

HY-103333

Arvanil N-Vanillylarachidonamide	TRP Channel Cannabinoid Receptor	Neurological Disease
Arvanil is a ligand for *vanilloid receptor* 1 (VR1)** and cannabinoid 1 (CB1). Arvanil can inhibit spasticity, as a potent neuroprotectant.

HY-132217

CB2 receptor agonist 2	Cannabinoid Receptor	Neurological Disease
CB2 receptor agonist 2 is a potent and selective agonist for the CB2 (cannabinoid type 2) receptor with a K_i of 8.5 nM. CB2 receptor agonist 2 has high affinity and selectivity for CB2.

HY-14167

GW842166X	Cannabinoid Receptor	Inflammation/Immunology Neurological Disease
GW842166X is a potent and selective cannabinoid receptor 2 (CB2) agonist with IC₅₀ values of 63 and 91 nM for human and rat CB2, respectively.

HY-111110

Olorinab APD 371	Cannabinoid Receptor	Neurological Disease
Olorinab (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 (CB₂) agonist, with an EC₅₀ of 6.2 nM for hCB₂.

HY-150029

CB1/2 agonist 3	Cannabinoid Receptor	Neurological Disease
CB1/2 agonist 3 (compound 52), a potent non-selective cannabinoid ligand, is a CB1/CB2 (cannabinoid receptor) competitive agonist. CB1/2 agonist 3 acts on hCB1 and hCB2 with K_i values of 5.9 nM and 3.5 nM, respectively.

HY-121616

(R)-SLV 319	Cannabinoid Receptor	Neurological Disease
(R)-SLV 319 is a potent and selective cannabinoid receptor 1 (CB1) antagonist with a K_i value of 894 nM. (R)-SLV 319 is a dextrorotatory counterpart of SLV 319

HY-10013B

Taranabant ((1R,2R)stereoisomer) MK0364 (1R,2R)stereoisomer	Cannabinoid Receptor	Others
Taranabant (1R,2R)stereoisomer is the R-enantiomer of Taranabant. Taranabant is a highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist.

HY-110014

Noladin ether	Cannabinoid Receptor	Neurological Disease
Noladin ether is a potent and selective agonist of **cannabinoid CB₁ receptor, with a K_i** of 21.2 nM. Noladin ether can cause hypothermia, intestinal immobility, and mild antinociception.

HY-W005629

Leelamine	Cannabinoid Receptor PDHK	Cancer
Leelamine is a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine also inhibits pyruvate dehydrogenase kinases (PDKs). Leelamine exhibits anti-tumor activity.

HY-116637

Tetrahydromagnolol Magnolignan	Cannabinoid Receptor GPR55	Inflammation/Immunology
Tetrahydromagnolol (Magnolignan), a main metabolite of Magnolol, is a potent and selective **cannabinoid CB2 receptor agonist with an EC₅₀ of 170 nM and a K_i** of 416 nM. Tetrahydromagnolol possesses 20-fold more selective for CB2 receptor than CB1 receptor. Tetrahydromagnolol is also a weak GPR55 receptor antagonist.

HY-10013

Taranabant MK-0364	Cannabinoid Receptor	Metabolic Disease
Taranabant is a highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist that inhibits the binding and functional activity of various agonists, with a binding K_i of 0.13 nM for the human CB1R in vitro.

HY-110020

rel-O-2050
Cannabinoid Receptor Metabolic Disease

rel-O-2050 (Compound O-2050) is a neutral cannabinoid CB₁ receptor antagonist. rel-O-2050 also decreases food intake in mice.

rel-O-2050	Cannabinoid Receptor	Metabolic Disease
rel-O-2050 (Compound O-2050) is a neutral **cannabinoid CB₁ receptor** antagonist. rel-O-2050 also decreases food intake in mice.

HY-124283A

LEI-101	Cannabinoid Receptor	Neurological Disease
LEI-101 is a potent, selective, and orally bioavailable **cannabinoid CB2 receptor** agonist, with a pEC₅₀ of 8 for hCB2, and a pK_i of less than 4 for hERG. LEI-101 is ~100-fold more potent in binding to CB2 receptors than to CB1 receptors.

HY-15443

AM251	Cannabinoid Receptor	Neurological Disease
AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC₅₀ of 8 nM. AM251 also acts as a potent GPR55 agonist with an EC₅₀ of 39 nM.

HY-14137

Rimonabant Hydrochloride SR 141716A Hydrochloride	Cannabinoid Receptor Bacterial	Cancer Infection Metabolic Disease
Rimonabant Hydrochloride (SR 141716A Hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an K_i of 1.8 nM. Rimonabant Hydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).

HY-116418

Virodhamine	Endogenous Metabolite Cannabinoid Receptor	Neurological Disease
Virodhamine is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases.

HY-119744

BAY 38-7271	Cannabinoid Receptor	Neurological Disease
BAY 38-7271 is selective and highly potent and cannabinoid CB₁/CB₂ receptor agonist, with K_is of 1.85 nM and 5.96 nM for recombinant human CB₁ receptor and CB₂ receptor, respectively. BAY 38-7271 has strong neuroprotective properties.

HY-141411A

Zevaquenabant (S)-MRI-1867	Cannabinoid Receptor NO Synthase	Metabolic Disease
Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD).

HY-100488

Bay 59-3074	Cannabinoid Receptor	Cancer
Bay 59-3074 is a selective cannabinoid CB₁/CB₂ receptor partial agonist with K_i values of 48.3 and 45.5 nM at human CB₁ and CB₂ receptors, respectively. Bay 59-3074 has analgesic properties.

HY-14136

Rimonabant SR141716	Cannabinoid Receptor Bacterial	Infection Metabolic Disease Cancer
Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a K_i of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).

HY-147532

CB2R probe 1	Cannabinoid Receptor	Cancer
CB2R probe 1 is a safe and green CB2R (cannabinoid 2 receptor) fluorescent probe with an K_i of 130 nM. CB2R probe 1 shows low cytotoxicity in cancer cells.

HY-103326

NIDA-41020	Cannabinoid Receptor	Neurological Disease
NIDA-41020 is a potent and selective cannabinoid receptor 1(CB1) antagonist with a K_i of 4.1 nM. NIDA-41020 was designed as a potential radioligand for use in positron emission tomography (PET).

HY-121827

LH21	Cannabinoid Receptor	Metabolic Disease
LH-21 is a potent in vivo neutral cannabinoid CB1 receptor antagonist. LH-21 reduces food intake and body weight gain in obese Zucker rats. , and displays efficacy as a feeding inhibitor.

HY-112340

TM38837	Cannabinoid Receptor	Metabolic Disease
TM38837 is a peripheral selective cannabinoid receptor type 1 (CB1) receptor antagonist. TM38837 shows limited penetrance to the brain in order to minimize or prevent CNS adverse reactions, and preserves potential antiobesity effects. TM38837 reduces propensity for psychiatric side effects.

HY-107471

CB2 receptor agonist 3 GP2a	Cannabinoid Receptor	Cancer
CB2 receptor agonist 3 is a robust and selective CB2 cannabinoid agonist with K_is of 7.6 and 900 nM for CB2 and CB1, respectively. CB2 receptor agonist 3 significantly increases P-ERK 1/2 expression in HL-60 cells.

HY-112707

AM9405	Cannabinoid Receptor 5-HT Receptor	Neurological Disease
AM9405 is a novel peripherally active cannabinoid type 1 (CB1) and serotonin type 3 receptor agonist. AM9405 inhibits twitch contraction of the ileum and the colon with IC₅₀s of 45.71 and 0.076 nM, respectively.

HY-15451

MDA 19	Cannabinoid Receptor	Neurological Disease
MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a K_i of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity.

HY-12095

CB1 inverse agonist 2	Cannabinoid Receptor	Neurological Disease
CB1 inverse agonist 2 is an orally active inverse agonist of Cannabinoid Receptor CB1. CB1 inverse agonist 2 effectively inhibits CP55940-induced hypothermia and anorexia in mice model.

HY-W013788

2-Palmitoylglycerol 2-Palm-Gl	Cannabinoid Receptor	Neurological Disease
2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119.

HY-131004

CB2R PAM	Cannabinoid Receptor	Neurological Disease
CB2R PAM is an orally active cannabinoid type-2 receptors (CB2Rs) positive allosteric modulator. CB2R PAM displays antinociceptive activity in vivo in an experimental mouse model of neuropathic pain.

HY-141411

(Rac)-Zevaquenabant (Rac)-MRI-1867	Cannabinoid Receptor NO Synthase	Others
(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB₁R)/iNOS antagonist, with a K_i of 5.7 nM for CB₁R. (Rac)-Zevaquenabant is potential for the research of liver fibrosis.

HY-110028

Leelamine hydrochloride	Cannabinoid Receptor Fatty Acid Synthase (FASN) Androgen Receptor	Cancer Endocrinology
Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees. Leelamine hydrochloride is a cannabinoid receptor type 1 (CB1) agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of androgen receptor, which is known to regulate fatty acid synthesis^[2,3].

HY-14900

Tedalinab GRC-10693	Cannabinoid Receptor	Inflammation/Immunology
Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment.

HY-14136S

Rimonabant-d10 SR141716-d₁₀	Cannabinoid Receptor Bacterial	Infection Metabolic Disease Cancer
Rimonabant-d₁₀ is deuterium labeled Rimonabant. Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a Ki of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).

HY-110036

GW-405833 L768242	Cannabinoid Receptor	Inflammation/Immunology Neurological Disease
GW-405833 (L768242) is a potent, selective cannabinoid receptor 2 (CB₂) agonist with an EC₅₀ of 50.7 nM. GW-405833 also behaves as a noncompetitive CB₁ antagonist. GW-405833 suppresses inflammatory and neuropathic pain.

HY-123410

KM-233	Cannabinoid Receptor	Cancer
KM-233 is a classical cannabinoid with good blood brain barrier penetration. KM-233 possesses a selective affinity for the CB2 receptors relative to THC. KM-233 is effective at reducing U87 glioma tumor burden, and can be used for glioma research.

HY-14137S

Rimonabant-d10 hydrochloride	Cannabinoid Receptor Bacterial	Cancer Infection Metabolic Disease
Rimonabant-d₁₀ (hydrochloride) is the deuterium labeled Rimonabant hydrochloride. Rimonabant hydrochloride (SR 141716A hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an Ki of 1.8 nM. Rimonabant hHydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3)[1][2].

HY-P1091

Hemopressin (human, mouse)	Cannabinoid Receptor	Neurological Disease
Hemopressin is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin exerts antinociceptive action in inflammatory pain models.

HY-119104

AZD1940	Cannabinoid Receptor	Neurological Disease
AZD1940 is an orally active, high affinity **cannabinoid CB1/CB2 receptor agonist with pK_i values of 7.93 and 9.06 for human CB1R and CB2R**, respectively. AZD1940 shows a robust analgesia action.

HY-P1091A

Hemopressin(human, mouse) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin TFA exerts antinociceptive action in inflammatory pain models.

HY-147707

CB2 receptor antagonist 1	Cannabinoid Receptor	Others
Hexyl resorcinol derivative 29 has been proved to be a CB2 selective competitive antagonist / reverse agonist with good potency. Olivanol and 5- (2-methyloctane-2-yl) resorcinol derivatives 23 and 24 showed significant antinociceptive activity. Compound 24 was shown to activate cannabinoid and TRPV1 receptors.

HY-P1090

Hemopressin(rat)	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) exerts antinociceptive action in inflammatory pain models.

HY-14791

Ibipinabant SLV319; BMS-646256	Cannabinoid Receptor	Metabolic Disease
Ibipinabant (SLV319) is a potent, selective and orally active antagonist of **cannabinoid CB1 receptor, with a K_i** of 7.8 nM. Ibipinabant shows more than 1000-fold selectivity for CB1 over CB2 (K_i=7943 nM). Ibipinabant can be used for the research of obesity and diabetic.

HY-W127407

Glycerophospho-N-arachidonoyl ethanolamine	Biochemical Assay Reagents	Others
Glycerophospho-N-Arachidonoyl Ethanolamine is a N-acylated ethanolamines (NAEs). Most NAEs are naturally occurring lipids with diverse biological activities. Different types of NAE can be derived from glycerophosphate-linked precursors through the activity of glycerophosphodiesterase 1 (GDE1). Glycerophosphate-N-Arachidonoyl Ethanolamine is the precursor of Anandamide (AEA), also known as Anandamide. AEA is an endocannabinoid neurotransmitter that binds to central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. It inhibits the specific binding of [3H]-HU-243 to synaptosomal membranes with a Ki value of 52 nM compared to 46 nM for δ9-THC.

HY-120851

O-7460	Cannabinoid Receptor	Metabolic Disease
O-7460 is a potent and selective DAGLα inhibitor, with an IC₅₀ of 0.69 μM. O-7460 shows selectivity over onoacylglycerol lipase (MAGL), human CB1 and CB2 cannabinoid receptors. O-7460 can decrease HFD-caused an up-regulation of 2-AG levels.

HY-P1090A

Hemopressin(rat) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) TFA exerts antinociceptive action in inflammatory pain models.

HY-118140

ZCZ011	Cannabinoid Receptor	Inflammation/Immunology Neurological Disease
ZCZ011 is a potent and brain penetrant **cannabinoid 1 (CB1) receptor** positive allosteric modulator. ZCZ011 potentiates binding of CP55,940 to the CB1 receptor, enhances anandamide (AEA)-stimulated GTPγS binding in mouse brain membranes. ZCZ011 increases β-arrestin recruitment and ERK phosphorylation in hCB1 cells. ZCZ011 can be used for researching neuropathic and inflammatory pain.

HY-145153

S-777469	Cannabinoid Receptor	Neurological Disease
S-777469 is a selective and orally available cannabinoid type 2 receptor (CB2) agonist with a K_i of 36 nM. S-777469 significantly suppresses compound 48/80-induced scratching behavior in mice in a dose-dependent manner. S-777469 produces its antipruritic effects by inhibiting itch signal transmission through CB2 agonism.

HY-W008364

Olivetol	Cytochrome P450 Cannabinoid Receptor	Neurological Disease
Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and CB2. Olivetol also inhibits CYP2C19 and CYP2D6 activity, with IC₅₀s of 15.3 μM, 7.21 μM and K_is of 2.71 μM, 2.87 μM, respectively.

HY-B0151

Pregnenolone 3β-Hydroxy-5-pregnen-20-one	Cannabinoid Receptor TRP Channel Endogenous Metabolite Autophagy	Neurological Disease
Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of **cannabinoid CB1 receptor*, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication. Pregnenolone is also a TRPM3 channel* activator, and also can weakly activate TRPM1 channels.

HY-145196

RTICBM-189	Cannabinoid Receptor	Neurological Disease
RTICBM-189 is a potent, brain-penetrant allosteric modulator of the cannabinoid type-1 (CB₁) receptor with a pIC₅₀ of 7.54 in Ca²⁺ mobilization assay. RTICBM-189 has pIC₅₀s of 5.29 and 6.25 for hCB₁ and mCB₁, respectively. RTICBM-189 significantly and selectively attenuates the reinstatement of the addictive agent-seeking behavior in rats.

HY-144705

GAT564	Cannabinoid Receptor	Neurological Disease
GAT564 (Compound 15d) is a potent allosteric modulator of cannabinoid 1 receptor (CB1R) with EC₅₀s of 87 and 320 nM respectively for cAMP and β-arrestin2. GAT564 markedly promotes orthosteric ligand binding to hCB1R. GAT564 is efficacious as a topical agent that significantly reduces intraocular pressure (IOP) in the ocular normotensive murine model of glaucoma.

HY-150028

CB1/2 agonist 2	Cannabinoid Receptor	Inflammation/Immunology
CB1/2 agonist 2 (compound 23) is a potent non-selective cannabinoid ligand, with K_i values of 3.5 and 1.2 nM, respectively. CB1/2 agonist 2 can behave as a full CB1 agonist and CB2 competitive inverse agonist. CB1/2 agonist 2 shows antinociceptive activity.

HY-152576

CB2R agonist 1	Cannabinoid Receptor	Inflammation/Immunology
CB2R agonist 1 is a selective ligand of cannabinoid receptor subtype 2 (CB2R) with an EC₅₀ value of 0.56 µM. CB2R agonist 1 has high affinity and excellent selectivity for human CB2R and CB1R respectively. CB2R agonist 1 regulates the production of pro-inflammatory cytokines and anti-inflammatory cytokines and play an immunomodulatory role.

HY-110189

Pregnenolone monosulfate sodium 3β-Hydroxy-5-pregnen-20-one monosulfate sodium	Cannabinoid Receptor TRP Channel Endogenous Metabolite Autophagy	Neurological Disease
Pregnenolone monosulfate sodium (3β-Hydroxy-5-pregnen-20-one monosulfate sodium) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate sodium acts as a signaling-specific inhibitor of **cannabinoid CB1 receptor*, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate sodium can protect the brain from cannabis intoxication. Pregnenolone monosulfate sodium is also a TRPM3 channel* activator, and also can weakly activate TRPM1 channels.

HY-B1739

Pregnenolone monosulfate 3β-Hydroxy-5-pregnen-20-one monosulfate	Cannabinoid Receptor TRP Channel Endogenous Metabolite Autophagy	Neurological Disease
Pregnenolone monosulfate (3β-Hydroxy-5-pregnen-20-one monosulfate) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate acts as a signaling-specific inhibitor of **cannabinoid CB1 receptor*, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate can protect the brain from cannabis intoxication. Pregnenolone monosulfate is also a TRPM3 channel* activator, and also can weakly activate TRPM1 channels.

HY-150030

CB1/2 agonist 4	Cannabinoid Receptor	Neurological Disease
CB1/2 agonist 4 is a full CB1 agonist and CB2 partial agonist with EC₅₀ values of 15.09 nM and 1.16 nM, respectively. CB1/2 agonist 4 also has hCB1 and hCB2 receptor affinities with K_i values of 1.1 nM and 4.2 nM, respectively. CB1/2 agonist 4 has a significant antinociceptive activity, and also can activate cannabinoid and TRPV1 receptor with values of IC₅₀ and EC₅₀ is 0.8 μM and 0.12 μM, respectively.

HY-B0151S1

Pregnenolone-13C2,d2 3β-Hydroxy-5-pregnen-20-one-¹³C₂,d₂	Isotope-Labeled Compounds TRP Channel Endogenous Metabolite Cannabinoid Receptor Autophagy	Neurological Disease
Pregnenolone-¹³C₂,d₂ is the deuterium and ¹³C labeled Pregnenolone (HY-B0151). Pregnenolone is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[1][2][3][4].

HY-B0151S

Pregnenolone-d4 3β-Hydroxy-5-pregnen-20-one-d₄	Cannabinoid Receptor TRP Channel Endogenous Metabolite Autophagy	Neurological Disease
Pregnenolone-d₄ is the deuterium labeled Pregnenolone. Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication[1][2]. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].

HY-B0151S2

Pregnenolone-d4-1 3β-Hydroxy-5-pregnen-20-one-d₄-1	Cannabinoid Receptor TRP Channel Endogenous Metabolite Autophagy	Neurological Disease
Pregnenolone-d₄-1 is the deuterium labeled Pregnenolone. Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication[1][2]. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].

HY-110189S1

Pregnenolone monosulfate-d4 sodium 3β-Hydroxy-5-pregnen-20-one monosulfate-d₄ (sodium)	Cannabinoid Receptor TRP Channel Endogenous Metabolite Autophagy
Pregnenolone monosulfate-d₄ (sodium) is the deuterium labeled Pregnenolone monosulfate. Pregnenolone monosulfate sodium (3β-Hydroxy-5-pregnen-20-one monosulfate sodium) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate sodium acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate sodium can protect the brain from cannabis intoxication[1][2]. Pregnenolone monosulfate sodium is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].

HY-135880

OMDM-3
Endogenous Metabolite Neurological Disease

OMDM-3 is a selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i of 16.6 μM.
HY-135880A

OMDM-4
Endogenous Metabolite Neurological Disease

OMDM-4 is a selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i 17.7 μM.
HY-121557

OMDM-1
Endogenous Metabolite Neurological Disease

OMDM-1 is a potent, selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i of 2.4 μM.
HY-103342

OMDM-2
Endogenous Metabolite Neurological Disease

OMDM-2 is a potent, selective and metabolically stable inhibitor of anandamide cellular uptake (ACU), with a K_i of 3.0 μM.

HY-110189S

Pregnenolone monosulfate sodium-13C2,d2 3β-Hydroxy-5-pregnen-20-one monosulfate (sodium)-¹³C₂,d₂	Cannabinoid Receptor TRP Channel Endogenous Metabolite Autophagy	Neurological Disease
Pregnenolone monosulfate (sodium)-¹³C₂,d₂ is the ¹³C- and deuterium labeled Pregnenolone monosulfate sodium. Pregnenolone monosulfate sodium (3β-Hydroxy-5-pregnen-20-one monosulfate sodium) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate sodium salt acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate sodium salt can protect the brain from cannabis intoxication[1][2]. Pregnenolone monosulfate sodium salt is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].

HY-152581

CB2R-IN-3	Cannabinoid Receptor	Inflammation/Immunology
CB2R-IN-3 is a selective antagonist of cannabinoid type 2 receptor (CB2R). CB2R-IN-3 has high affinity for human CB2R and specific selectivity for CB1R. CB2R-IN-3 can be combined with CB65 (HY-110047), the activator of CB2R. CB2R-IN-3 effectively up-regulates the expression of anti-inflammatory cytokines and down-regulates the expression of pro-inflammatory cytokines.

Cat. No.	Product Name

HY-L006

GPCR/G Protein Compound Library

2032 compounds

GPCRs are a large family of cell surface receptors that respond to a variety of external signals. Binding of a signaling molecule to a GPCR results in G protein activation, which in turn triggers the production of any number of second messengers. GPCRs play an important role in the human body, and increased understanding of these receptors has greatly affected modern medicine. In fact, researchers estimate that between one-third to one-half of all approved drugs act by binding to GPCRs. GPCRs are a large group of drug targets in drug discovery.

MCE provides a unique collection of 2032 small molecules targeting GPCRs that can be used in the screening for various GPCRs-related research and drug development projects.

Cat. No.	Product Name	Type

HY-W127407

Glycerophospho-N-arachidonoyl ethanolamine

Biochemical Assay Reagents

Glycerophospho-N-Arachidonoyl Ethanolamine is a N-acylated ethanolamines (NAEs). Most NAEs are naturally occurring lipids with diverse biological activities. Different types of NAE can be derived from glycerophosphate-linked precursors through the activity of glycerophosphodiesterase 1 (GDE1). Glycerophosphate-N-Arachidonoyl Ethanolamine is the precursor of Anandamide (AEA), also known as Anandamide. AEA is an endocannabinoid neurotransmitter that binds to central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. It inhibits the specific binding of [3H]-HU-243 to synaptosomal membranes with a Ki value of 52 nM compared to 46 nM for δ9-THC.

Cat. No.	Product Name	Target	Research Area

HY-152270

Pirnabine
Cannabinoid Receptor Neurological Disease

Pirnabine is a cannabinoid receptor ligand. Pirnabine can be used for the research of glaucoma.

HY-P1397

RVD-Hpα	Cannabinoid Receptor	Neurological Disease
RVD-Hpα, an α-hemoglobin-derived peptide containing three additional amino acids, is a CB1 cannabinoid receptor agonist. RVD-Hpα is a positive allosteric modulator of cannabinoid receptor 2.

HY-P1091

Hemopressin (human, mouse)	Cannabinoid Receptor	Neurological Disease
Hemopressin is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin exerts antinociceptive action in inflammatory pain models.

HY-P1091A

Hemopressin(human, mouse) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin TFA exerts antinociceptive action in inflammatory pain models.

HY-P1090

Hemopressin(rat)	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) exerts antinociceptive action in inflammatory pain models.

HY-P1090A

Hemopressin(rat) TFA	Cannabinoid Receptor	Neurological Disease
Hemopressin(rat) TFA is a nonapeptide derived from the α1-chain of hemoglobin, is originally isolated from rat brain homogenates. Hemopressin(rat) TFA is orally active, selective and inverse agonist of CB1 cannabinoid receptors. Hemopressin(rat) TFA exerts antinociceptive action in inflammatory pain models.

Cat. No.	Product Name	Target	Category

HY-N6932

Voacamine	Cannabinoid Receptor P-glycoprotein	Indole Alkaloids Alkaloids Structural Classification other families Plants Source classification Metabolic Disease Disease Research Fields Classification of Application Fields
Voacamine, an indole alkaloid, exhibits potent **cannabinoid CB1 receptor antagonistic activity. Voacamine also inhibits P-glycoprotein (P-gp**) action in multidrug-resistant tumor cells.

HY-N0919

Yangonin	Cannabinoid Receptor NF-κB Autophagy	Other Phenylpropanoids Phenylpropanoids Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants other families
Yangonin exhibits affinity for the human recombinant cannabinoid CB1 receptor with an IC₅₀ and a K_i of 1.79 μM and 0.72 μM, respectively.

HY-116637

Tetrahydromagnolol Magnolignan	Cannabinoid Receptor GPR55	Phenols Polyphenols Structural Classification Magnoliaceae Magnolia Liliflora Desr. Plants Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
Tetrahydromagnolol (Magnolignan), a main metabolite of Magnolol, is a potent and selective **cannabinoid CB2 receptor agonist with an EC₅₀ of 170 nM and a K_i** of 416 nM. Tetrahydromagnolol possesses 20-fold more selective for CB2 receptor than CB1 receptor. Tetrahydromagnolol is also a weak GPR55 receptor antagonist.

HY-W013788

2-Palmitoylglycerol 2-Palm-Gl	Cannabinoid Receptor	Natural Products Source classification Endogenous metabolite
2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119.

HY-110028

Leelamine hydrochloride	Cannabinoid Receptor Fatty Acid Synthase (FASN) Androgen Receptor	Terpenoids Structural Classification Diterpenoids Pinus massoniana Lamb. Pinaceae other families Plants Source classification Disease Research Fields Classification of Application Fields Endocrinology
Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees. Leelamine hydrochloride is a cannabinoid receptor type 1 (CB1) agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. Leelamine hydrochloride suppresses transcriptional activity of androgen receptor, which is known to regulate fatty acid synthesis^[2,3].

HY-W008364

Olivetol	Cytochrome P450 Cannabinoid Receptor	Phenols Polyphenols Structural Classification Microorganisms other families Plants Source classification
Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and CB2. Olivetol also inhibits CYP2C19 and CYP2D6 activity, with IC₅₀s of 15.3 μM, 7.21 μM and K_is of 2.71 μM, 2.87 μM, respectively.

HY-B0151

Pregnenolone 3β-Hydroxy-5-pregnen-20-one	Cannabinoid Receptor TRP Channel Endogenous Metabolite Autophagy	Steroids Neurological Disease Disease Research Fields Anti-aging Classification of Application Fields Source classification Endogenous metabolite
Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of **cannabinoid CB1 receptor*, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication. Pregnenolone is also a TRPM3 channel* activator, and also can weakly activate TRPM1 channels.

HY-110189

Pregnenolone monosulfate sodium 3β-Hydroxy-5-pregnen-20-one monosulfate sodium	Cannabinoid Receptor TRP Channel Endogenous Metabolite Autophagy	Steroids Source classification Endogenous metabolite
Pregnenolone monosulfate sodium (3β-Hydroxy-5-pregnen-20-one monosulfate sodium) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate sodium acts as a signaling-specific inhibitor of **cannabinoid CB1 receptor*, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate sodium can protect the brain from cannabis intoxication. Pregnenolone monosulfate sodium is also a TRPM3 channel* activator, and also can weakly activate TRPM1 channels.

HY-B1739

Pregnenolone monosulfate 3β-Hydroxy-5-pregnen-20-one monosulfate	Cannabinoid Receptor TRP Channel Endogenous Metabolite Autophagy	Steroids Source classification Endogenous metabolite
Pregnenolone monosulfate (3β-Hydroxy-5-pregnen-20-one monosulfate) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate acts as a signaling-specific inhibitor of **cannabinoid CB1 receptor*, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate can protect the brain from cannabis intoxication. Pregnenolone monosulfate is also a TRPM3 channel* activator, and also can weakly activate TRPM1 channels.

Recombinant Proteins Recommended:

Cannabinoid Receptor

Species:	Human (2)
Tag:	His (1)
Source:	HEK293 (2)

Cat. No.	Product Name	Species	Source

HY-P700636

CNR2 Protein-VLP, Human (HEK293)
CNR2; Cannabinoid Receptor 2 (macrophage); Cannabinoid Receptor 2; CB2
Human HEK293

HY-P700408

CNR1 Protein-VLP, Human (HEK293, His) Cannabinoid Receptor 1 (brain); CNR; Cannabinoid Receptor 1; CANN6; CB R; CB1; CB1A; CB1K5; central Cannabinoid Receptor; CB-R; CB1R	Human	HEK293
CNR1 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays.

Cat. No.	Product Name

HY-14136S

Rimonabant-d10
Rimonabant-d₁₀ is deuterium labeled Rimonabant. Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a Ki of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).

HY-14137S

Rimonabant-d10 hydrochloride
Rimonabant-d₁₀ (hydrochloride) is the deuterium labeled Rimonabant hydrochloride. Rimonabant hydrochloride (SR 141716A hydrochloride) is a highly potent and selective central cannabinoid receptor (CB1) antagonist with an Ki of 1.8 nM. Rimonabant hHydrochloride (SR 141716A Hydrochloride) also inhibits Mycobacterial membrane protein Large 3 (MMPL3)[1][2].

HY-B0151S1

Pregnenolone-13C2,d2

Pregnenolone-¹³C₂,d₂ is the deuterium and ¹³C labeled Pregnenolone (HY-B0151). Pregnenolone is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[1][2][3][4].

HY-B0151S

Pregnenolone-d4

Pregnenolone-d₄ is the deuterium labeled Pregnenolone. Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication[1][2]. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].

HY-B0151S2

Pregnenolone-d4-1

Pregnenolone-d₄-1 is the deuterium labeled Pregnenolone. Pregnenolone (3β-Hydroxy-5-pregnen-20-one) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone can protect the brain from cannabis intoxication[1][2]. Pregnenolone is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].

HY-110189S1

Pregnenolone monosulfate-d4 sodium

Pregnenolone monosulfate-d₄ (sodium) is the deuterium labeled Pregnenolone monosulfate. Pregnenolone monosulfate sodium (3β-Hydroxy-5-pregnen-20-one monosulfate sodium) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate sodium acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate sodium can protect the brain from cannabis intoxication[1][2]. Pregnenolone monosulfate sodium is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].

HY-110189S

Pregnenolone monosulfate sodium-13C2,d2

Pregnenolone monosulfate (sodium)-¹³C₂,d₂ is the ¹³C- and deuterium labeled Pregnenolone monosulfate sodium. Pregnenolone monosulfate sodium (3β-Hydroxy-5-pregnen-20-one monosulfate sodium) is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate sodium salt acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of tetrahydrocannabinol (THC) that are mediated by the CB1 receptors. Pregnenolone monosulfate sodium salt can protect the brain from cannabis intoxication[1][2]. Pregnenolone monosulfate sodium salt is also a TRPM3 channel activator, and also can weakly activate TRPM1 channels[3].

Cannabinoid Receptor

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Natural
Products